Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CMPS 
Compass Pathways Plc (CMPS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: CMPS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $19.42
1 Year Target Price $19.42
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 772.94M USD | Price to earnings Ratio - | 1Y Target Price 19.42 |
Price to earnings Ratio - | 1Y Target Price 19.42 | ||
Volume (30-day avg) 11 | Beta 1.93 | 52 Weeks Range 2.25 - 8.90 | Updated Date 02/21/2026 |
52 Weeks Range 2.25 - 8.90 | Updated Date 02/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.43% | Return on Equity (TTM) -205.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 407106025 | Price to Sales(TTM) - |
Enterprise Value 407106025 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.51 | Shares Outstanding 96017044 | Shares Floating 69282058 |
Shares Outstanding 96017044 | Shares Floating 69282058 | ||
Percent Insiders 11.06 | Percent Institutions 62.49 |
Upturn AI SWOT
Compass Pathways Plc
Company Overview
History and Background
Compass Pathways Plc was founded in 2016 with the mission to transform mental healthcare by developing innovative psilocybin-based therapies. A significant milestone was its initial public offering (IPO) on the Nasdaq stock exchange in September 2020, which raised substantial capital to further its research and development. The company has evolved by focusing on clinical trials for its proprietary psilocybin therapy, COMP360, for treatment-resistant depression and other mental health conditions.
Core Business Areas
- Psychedelic Therapy Development (COMP360): Compass Pathways is primarily focused on the research, development, and clinical testing of its proprietary psilocybin therapy, COMP360, for various mental health indications. This includes formulation, manufacturing, and conducting clinical trials to assess safety and efficacy.
- Clinical Trial Operations: The company is actively engaged in designing and executing clinical trials, ranging from Phase 1 to Phase 3, to evaluate the therapeutic potential of COMP360 in conjunction with psychological support.
- Therapeutic Ecosystem Development: Compass Pathways is also building a network of trained mental health professionals and clinics to administer its therapy once it receives regulatory approval.
Leadership and Structure
Compass Pathways Plc is led by a management team with extensive experience in the pharmaceutical and mental health sectors. Key leadership positions include Chief Executive Officer, Chief Medical Officer, and Chief Financial Officer. The company operates as a research and development organization with a strong focus on clinical operations and regulatory affairs. Its structure is designed to support the rigorous scientific and regulatory pathways required for novel drug development.
Top Products and Market Share
Key Offerings
- COMP360 Psilocybin Therapy: COMP360 is Compass Pathways' flagship product, a proprietary formulation of psilocybin designed for therapeutic use in conjunction with carefully controlled psychological support. While COMP360 is still in clinical development and does not yet have market share data, its development is considered a pioneer in the emerging field of psychedelic-assisted therapy. Competitors in this nascent space include other companies developing psychedelic compounds (e.g., psilocybin, MDMA) for mental health, as well as traditional pharmaceutical companies exploring novel treatments for depression and other psychiatric disorders.
Market Dynamics
Industry Overview
The mental health therapeutics market is a significant and growing global industry, driven by increasing awareness of mental health issues and a demand for more effective treatment options. The emergence of psychedelic-assisted therapies represents a disruptive innovation within this sector, promising novel mechanisms of action for conditions that are often resistant to conventional treatments. The regulatory landscape for these novel therapies is still evolving.
Positioning
Compass Pathways is positioned as a leader in the development of psilocybin-based therapies for mental health conditions. Its key competitive advantages include its proprietary COMP360 formulation, its extensive clinical trial program, and its focus on building a complete therapeutic ecosystem. The company is at the forefront of clinical research for this class of compounds.
Total Addressable Market (TAM)
The TAM for mental health treatments, particularly for conditions like treatment-resistant depression, is substantial, estimated in the tens of billions of dollars globally. Compass Pathways, by targeting these significant unmet needs, is positioned to capture a portion of this market. The company's focus on scalable, evidence-based treatments aims to address a broad patient population.
Upturn SWOT Analysis
Strengths
- Pioneering psilocybin therapy research and development.
- Proprietary COMP360 formulation with potential for efficacy.
- Strong clinical trial program and experienced management team.
- Focus on a comprehensive therapeutic model (drug + therapy + training).
- Significant capital raised through IPO to fund R&D.
Weaknesses
- Reliance on regulatory approval for market entry.
- Long development timelines and high R&D costs.
- Uncertainty in the long-term safety and efficacy profile.
- Limited product pipeline beyond COMP360.
- Dependence on a novel and evolving regulatory framework.
Opportunities
- Growing demand for novel mental health treatments.
- Potential for wider acceptance and de-stigmatization of psychedelic therapies.
- Expansion into other mental health indications.
- Partnerships with healthcare providers and institutions.
- Advancements in drug delivery and combination therapies.
Threats
- Regulatory hurdles and delays in approval.
- Competition from other psychedelic therapy developers and traditional pharma.
- Potential for negative public perception or adverse events.
- Changes in drug pricing and reimbursement policies.
- Challenges in scaling manufacturing and treatment delivery.
Competitors and Market Share
Key Competitors
- Mind Medicine (MindMed) Inc. (MNMD)
- Oatsy Therapeutics
- Delix Therapeutics
Competitive Landscape
Compass Pathways' competitive advantages lie in its established clinical trials and proprietary COMP360 formulation. However, competitors like MindMed are also making significant strides with diverse psychedelic compounds and therapeutic approaches. The market share is fragmented as the industry is in its nascent stages, with significant opportunity for any company that achieves regulatory approval and demonstrates clear efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historically, Compass Pathways' growth has been marked by its establishment, securing significant funding through its IPO, and advancing its COMP360 therapy through early-stage clinical trials. The company has shown growth in its operational scale and the scope of its clinical programs.
Future Projections: Future growth projections for Compass Pathways are contingent on the successful completion of its ongoing clinical trials for COMP360, particularly Phase 3 trials. Positive results and subsequent regulatory approvals would pave the way for commercialization and significant revenue generation. Analyst estimates typically focus on the potential market penetration and peak sales of its therapies.
Recent Initiatives: Recent initiatives include the advancement of its Phase 2b and Phase 3 clinical trials for COMP360 in treatment-resistant depression, exploration of COMP360 for other indications, and ongoing efforts to build out its therapeutic network and operational infrastructure.
Summary
Compass Pathways Plc is a pioneering company in the emerging field of psychedelic-assisted therapy, with its COMP360 psilocybin therapy showing promise for treatment-resistant depression. The company's strengths lie in its strong clinical development program and experienced team, but it faces significant risks associated with regulatory approval and long development timelines. Opportunities for growth are substantial, driven by the unmet need in mental healthcare, while threats include intense competition and evolving regulatory landscapes. Strategic focus on clinical success and partnerships will be crucial for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (SEC)
- Financial News Outlets
- Industry Research Reports
- Market Data Providers
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor and conducting thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Pathways Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-18 | CEO & Director Mr. Kabir Kumar Nath M.A., M.B.A. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 166 | Website https://compasspathways.com |
Full time employees 166 | Website https://compasspathways.com | ||
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.